drugset / Trial / NCT06980532
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety
Timeline
- Start
- 2025-04-25
- Primary completion
- 2028-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 3 mg | Oral |
| Subject | Gumarontinib | Small molecule | 200 mg | Oral |
| Subject | Gumarontinib | Small molecule | 250 mg | Oral |